Pfizer Inc. (NYSE:PFE) Shares Sold by Highlander Capital Management LLC

Highlander Capital Management LLC lowered its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 3.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,103 shares of the biopharmaceutical company’s stock after selling 600 shares during the period. Highlander Capital Management LLC’s holdings in Pfizer were worth $885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Bank OZK boosted its position in shares of Pfizer by 0.3% during the 4th quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock worth $4,067,000 after acquiring an additional 195 shares in the last quarter. Winfield Associates Inc. lifted its position in shares of Pfizer by 0.9% during the 4th quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock worth $1,273,000 after buying an additional 200 shares during the last quarter. Birinyi Associates Inc. lifted its position in shares of Pfizer by 3.4% during the 1st quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 200 shares during the last quarter. Curbstone Financial Management Corp lifted its position in shares of Pfizer by 0.3% during the 1st quarter. Curbstone Financial Management Corp now owns 65,901 shares of the biopharmaceutical company’s stock worth $3,412,000 after buying an additional 200 shares during the last quarter. Finally, WFA of San Diego LLC lifted its position in shares of Pfizer by 3.3% during the 4th quarter. WFA of San Diego LLC now owns 6,345 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 201 shares during the last quarter. Institutional investors and hedge funds own 66.50% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the firm’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at $585,250.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Pfizer news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the firm’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 4,218 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total transaction of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares in the company, valued at $585,250.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,126 shares of company stock valued at $2,075,003. Corporate insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. Berenberg Bank set a $50.00 target price on Pfizer in a research report on Friday, May 27th. Morgan Stanley cut their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research report on Friday, July 8th. The Goldman Sachs Group set a $50.00 target price on shares of Pfizer in a research report on Friday, July 29th. SVB Leerink lowered their target price on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research report on Friday, July 29th. Finally, Barclays raised their target price on shares of Pfizer from $50.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Monday, August 1st. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Pfizer Stock Down 1.2 %

PFE opened at $49.27 on Friday. The business’s fifty day moving average is $51.09 and its two-hundred day moving average is $51.10. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The company has a market cap of $276.45 billion, a price-to-earnings ratio of 9.64, a PEG ratio of 0.61 and a beta of 0.67. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71.

Pfizer (NYSE:PFEGet Rating) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. The company had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a return on equity of 44.38% and a net margin of 28.92%. Pfizer’s quarterly revenue was up 46.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.07 earnings per share. Analysts anticipate that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.25%. The ex-dividend date of this dividend is Thursday, July 28th. Pfizer’s payout ratio is 31.31%.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.